Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adial Pharmaceuticals Inc ADIL

Healthcare
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is... see more

Recent & Breaking News (NDAQ:ADIL)

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

Accesswire January 9, 2020

Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries

Accesswire December 19, 2019

Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

Accesswire December 16, 2019

Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

Accesswire December 13, 2019

Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites

Accesswire October 29, 2019

Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker

Accesswire October 17, 2019

Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

Accesswire October 7, 2019

Adial Files Clinical Trial Application to Commence Phase 3 Trial

Accesswire October 1, 2019

Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

Accesswire September 25, 2019

Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

Accesswire September 11, 2019

Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

Accesswire September 5, 2019

Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell''

Accesswire August 6, 2019

Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare

Accesswire June 19, 2019

Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder

Accesswire June 13, 2019

Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization

Accesswire June 6, 2019

Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder

Accesswire May 7, 2019

Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City

Accesswire April 30, 2019

Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate

Accesswire April 22, 2019

Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award

Accesswire April 4, 2019

Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.

Accesswire April 3, 2019